Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S regarding a class action lawsuit following disappointing results from the "REDEFINE 1" trial of CagriSema, which led to a significant drop in the company's stock price [1]. Group 1: Company Performance - The "REDEFINE 1" trial, which investigated the efficacy and safety of subcutaneous CagriSema, reported a weight loss of 22.7% after 68 weeks, falling short of Novo's target of at least 25% [1]. - Following the announcement of the trial results, Novo Nordisk's stock price decreased by $18.44, closing at $85.00 per share [1]. Group 2: Shareholder Actions - Shareholders who purchased shares of NVO between November 2, 2022, and December 19, 2024, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is March 25, 2025 [2]. Group 3: Legal Context - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [3]. - The firm emphasizes its commitment to responsible business practices and good corporate citizenship [3].